Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | ABCB1 | P08183 | 3/20 | 0.36 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CA7 | P43166 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | PPARG | P37231 | 1/20 | 0.34 |
| ▸ | PPARD | Q03181 | 1/20 | 0.34 |
| ▸ | PPARA | Q07869 | 1/20 | 0.34 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30845326 | 0.87 | KMT2A (0.43) | ACHEKMT2AABCB1GAAKDM4E | |
| SCHEMBL24758815 | 0.87 | KMT2A (0.43) | ACHEKMT2AABCB1GAAKDM4E | |
| SCHEMBL3004098 | 0.84 | ACHE (0.44) | ACHEGAAPPARGPPARDPPARA | |
| SCHEMBL3014167 | 0.84 | ACHE (0.44) | ACHEGAAPPARGPPARDPPARA | |
| SCHEMBL3014162 | 0.84 | ACHE (0.44) | ACHEGAAPPARGPPARDPPARA | |
| SCHEMBL3014159 | 0.84 | ACHE (0.44) | ACHEGAAPPARGPPARDPPARA | |
| SCHEMBL837246 | 0.78 | TRPA1 (0.41) | KMT2AGAAKDM4EMAPTALDH1A1 | |
| SCHEMBL837245 | 0.78 | TRPA1 (0.41) | KMT2AGAAKDM4EMAPTALDH1A1 | |
| SCHEMBL30695648 | 0.77 | NPSR1 (0.49) | KMT2AABCB1KDM4EMEN1ALDH1A1 | |
| SCHEMBL850878 | 0.77 | NPSR1 (0.49) | KMT2AABCB1KDM4EMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120252770-A1 | Chemical Compounds 572 | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-10-04 | — | — | US | disclosed |
| US-20120252770-A1 | Chemical Compounds 572 | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-10-04 | — | — | US | disclosed |
| US-8143290-B2 | Chemical compounds 572 | ASTRAZENECA AB (SE) | 2012-03-27 | — | — | US | disclosed |
| US-8143290-B2 | Chemical compounds 572 | ASTRAZENECA AB (SE) | 2012-03-27 | — | — | US | disclosed |
| US-20110071194-A1 | Chemical Compounds 572 | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2011-03-24 | — | — | US | disclosed |
| US-20110071194-A1 | Chemical Compounds 572 | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2011-03-24 | — | — | US | disclosed |
| US-20100197644-A1 | Chemical Compounds 572 | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2010-08-05 | — | — | US | disclosed |
| US-20100197644-A1 | Chemical Compounds 572 | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2010-08-05 | — | — | US | disclosed |
| US-7728030-B2 | Chemical compounds 572 | ASTRAZENECA AB (SE) | 2010-06-01 | — | — | US | disclosed |
| US-7728030-B2 | Chemical compounds 572 | ASTRAZENECA AB (SE) | 2010-06-01 | — | — | US | disclosed |
| US-20080214641-A1 | Chemical compounds 572 | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2008-09-04 | — | — | US | disclosed |
| US-20080214641-A1 | Chemical compounds 572 | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2008-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214641-A1 | Chemical compounds 572 | ABCG2, ABCB1, CYP11B2 | ACHE 1521/4885KMT2A 4171/4885ABCB1 2/4885 |
| US-20100197644-A1 | Chemical Compounds 572 | ABCG2, ABCB1, CYP11B2 | ACHE 1521/4885KMT2A 4171/4885ABCB1 2/4885 |
| US-20120252770-A1 | Chemical Compounds 572 | ABCG2, ABCB1, CYP11B2 | ACHE 1521/4885KMT2A 4171/4885ABCB1 2/4885 |
| US-20110071194-A1 | Chemical Compounds 572 | ABCG2, ABCB1, CYP11B2 | ACHE 1521/4885KMT2A 4171/4885ABCB1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.